Browse the corpus

REFERENCES de Groot AN, van Dongen PW, Vree TB, et al, “Ergot Alkaloids. Current Status and Review of Clinical Pharmacology and Therapeutic Use Compared With Other Oxytocics in Obstetrics and Gynaecology,” Drugs , 1998, 56(4):523-35. [PubMed 9806101 ] Gillam MP, Fideleff H, Boquete HR, et al, “Prolactin Excess: Treatment and Toxicity,” Pediatr Endocrinol Rev , 2004, 2(suppl)1:108-14. [PubMed 16456489 ] Gortney JS, Fagan A, and Kissack JC, "Neuroleptic Malignant Syndrome Secondary to Quetiapine," Ann Pharmacother , 2009, 43(4):785-91. [PubMed 19299325 ] Lejoyeux M, et al, “Serotonin Syndrome: Incidence, Symptoms, and Treatment,” CNS Drugs , 1994, 2:132-43. Melmed S and Braunstein GD, “Bromocriptine and Pleuropulmonary Disease,” Arch Intern Med , 1989, 149(2):258-9. [PubMed 2916870 ] Molitch ME, “Management of Prolactinomas During Pregnancy,” J Reprod Med , 1999, 44(12 Suppl):1121-6. [PubMed 10649822 ] Morgans D, “Re: Parlodel,” Aust N Z J Obstet Gynaecol , 1995, 35(2):228-9. [PubMed 7677704 ] Mueller PS, Vester JW, and Fermaglich J, “Neuroleptic Malignant Syndrome. Successful Treatment With Bromocriptine,” JAMA , 1983, 249(3):386-8. [PubMed 6129331 ] Parkes D, “Drug Therapy: Bromocriptine,” N Engl J Med , 1979, 301(16):873-8. [PubMed 384250 ] Strawn JR, Keck PE Jr, and Caroff SN, "Neuroleptic Malignant Syndrome," Am J Psychiatry , 2007, 164(6):870-6. [PubMed 17541044 ] Topic 13022 Version 41.0 © 2013 UpToDate, Inc. All rights reserved. | Subscription and License Agreement | Release: 21.6- C21.56 Licensed to: AsanBook Dig. Med. Lib. | Support Tag: [0502-1.234.2.38-DECD7EA589-S244013.14]